NCOA3 was initially found to be amplified in breast cancer and was reported to be abnormally overexpressed in various cancer types, including ovarian, esophageal, colorectal, and breast cancer.[44] NCOA3 acts as an oncogene and its’ knockdown reduced the proliferation of nude mouse cancer cells and the growth of xenograft tumor cells, and increased cell apoptosis.[45, 46] NCOA3 also takes part in metabolism diseases. Here, NCOA3 is linked to breast cancer.